|
gptkb:Insulin-like_growth_factor_II
|
biomarker for certain cancers
|
|
gptkb:adenosine_deaminase
|
diagnosis of tuberculosis (pleural fluid ADA test)
|
|
gptkb:butyrylcholinesterase
|
identification of atypical enzyme variants
|
|
gptkb:butyrylcholinesterase
|
assessment of exposure to nerve agents
|
|
gptkb:P12277_(CK-MB)
|
biomarker for myocardial infarction
|
|
gptkb:Aspartate_transaminase
|
marker for myocardial infarction
|
|
gptkb:Insulin-like_growth_factor_I
|
monitoring growth hormone therapy
|
|
gptkb:Aspartate_transaminase
|
marker for liver damage
|
|
gptkb:lysosomal_acid_alpha-glucosidase
|
enzyme replacement therapy for Pompe disease
|
|
gptkb:maytansine
|
not used as a single agent due to toxicity
|
|
gptkb:human_carbonic_anhydrase_II
|
target for diuretics
|
|
gptkb:Aspartate_aminotransferase
|
marker for myocardial infarction
|
|
gptkb:hsa:3630
|
target of tocilizumab
|
|
gptkb:DKK1_gene
|
potential therapeutic target
|
|
gptkb:glucocerebrosidase
|
enzyme replacement therapy
|
|
gptkb:butyrylcholinesterase
|
diagnosis of liver function
|
|
gptkb:hsa:3630
|
target of sarilumab
|
|
gptkb:Aspartate_aminotransferase
|
marker for liver damage
|
|
gptkb:human_carbonic_anhydrase_II
|
target for glaucoma drugs
|
|
gptkb:matrix_metalloproteinases
|
biomarkers for disease
|